



## Seres Therapeutics to Present at Three Upcoming March Conferences

March 5, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2019-- [Seres Therapeutics, Inc.](https://www.businesswire.com/news/home/20190305005942/en/) (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences:

- **Chardan's Inaugural Microbiome Summit** : a corporate overview will be presented on Thursday, March 7<sup>th</sup> at 8:10 a.m. ET in New York, NY.
- **Cowen and Company 39<sup>th</sup> Annual Health Care Conference**: a corporate overview will be presented on Monday, March 11<sup>th</sup> at 11:20 a.m. ET in Boston, MA.
- **Oppenheimer 29<sup>th</sup> Annual Healthcare Conference**: a corporate overview will be presented on Tuesday, March 19<sup>th</sup> at 11:30 a.m. ET in New York, NY.

A live audio webcast of each presentation will be available under the "Investors and Media" section of Seres' website. A replay will become available approximately one hour after each event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' most advanced program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for recurrent *C. difficile* infection. SER-287 is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190305005942/en/>

Source: Seres Therapeutics, Inc.

### IR or PR Contact:

Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467  
Vice President, Investor Relations and Corporate Communications  
[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)